Collagen Market (2026-2036)

In terms of volume, the global Collagen Market is expected to reach 990.9 KT by 2036 from an estimated 650.6 KT in 2026, registering a CAGR of 4.3% during the forecast period (2026-2036). Value is expected to grow faster than volume, reflecting the shift in product mix from gelatin toward collagen peptides, native collagen and medical-grade material, which command substantially higher prices per tonne.

The growth of this market is mainly driven by demand for collagen peptides in sports nutrition, weight management and functional food and beverage products; the use of gelatin in hard and soft capsules for pharmaceutical and nutraceutical dosage forms; the expansion of medical applications including wound dressing, tissue regeneration, implants and cardiology, where collagen provides a scaffold material with established biological performance; and the growth of marine and alternative sources addressing religious, dietary and supply considerations. In addition, raw material availability linked to meat and hide processing volumes, the improving margin structure of collagen producers, regulatory requirements governing animal-derived material in medical devices, and investment in recombinant and synthetic collagen production are further shaping the growth of this market.

The Collagen Market, also referred to as the collagen and gelatin market, collagen ingredients market, or collagen peptide market, comprises the structural protein recovered from animal tissue and supplied in processed forms for food, pharmaceutical, nutritional and medical use. The market includes gelatin produced by partial hydrolysis of collagen, collagen peptides produced by further enzymatic hydrolysis to low molecular weight fractions, native collagen supplied in its undenatured form, and synthetic and recombinant collagen produced without animal tissue. Material is recovered from bovine hides and bones, porcine skin and bones, fish skin and scales, chicken and sheep sources. The market ecosystem extends from meat processors and hide suppliers through collagen and gelatin manufacturers to food and beverage companies, pharmaceutical and nutraceutical formulators, sports nutrition brands, medical device manufacturers and the regulators whose requirements govern animal-derived material, health claims and device safety.

The commercial structure of this market is determined by the relationship between raw material and product mix. Hides, skins and bones are by-products of meat processing, so the available supply is governed by livestock slaughter volumes rather than by collagen demand, and producers cannot increase raw material availability by paying more. Value is therefore created by moving the same raw material into higher-value forms, and the clearest expression of that is the progression from gelatin to collagen peptides to purified native and medical-grade collagen, each commanding a higher price per tonne than the last.

Producer economics have improved substantially. In the second quarter of 2026, ended 4 July 2026, Darling Ingredients Inc., which describes itself as producing approximately 30% of the world collagen supply, reported Food Ingredients segment net sales of USD 408.5 million, up from USD 386.1 million, with segment gross margin of USD 148.3 million, equivalent to 36.3% of sales against 26.9% a year earlier, and segment adjusted EBITDA of USD 108.5 million, up from USD 69.9 million. An increase in segment gross margin from 26.9% to 36.3% of sales on sales growth of approximately 6% indicates that the improvement came from product mix, pricing and input cost rather than from volume, which is consistent with a market in which growth is realised in value ahead of tonnage.

Capacity decisions reflect that confidence. Darling Ingredients guided to third-quarter 2026 adjusted EBITDA of approximately USD 325 million to USD 340 million for its core ingredients business, and to capital expenditure of about USD 450.0 million for fiscal 2026. Investment at this level in a market where raw material supply is fixed is directed at conversion capability, including peptide hydrolysis, purification and specialty formulation, rather than at expanding gelatin tonnage, and it indicates that producers expect the mix shift toward higher-value forms to continue.

Raw material regulation has moved in the industry favour. On 13 July 2026, the European Commission adopted measures removing cattle hides, skins and leather from the product scope of the EU Deforestation Regulation, while confirming application of the Regulation from 30 December 2026 for large and medium-sized operators and from 30 June 2027 for other micro and small operators, with the delegated act remaining subject to scrutiny by the European Parliament and the Council. The removal of cattle hides, skins and leather from scope relieves collagen producers and their customers of traceability and due diligence obligations that would have applied to a by-product whose sourcing they do not control, although the geolocation and due diligence regime continues to apply to cattle and to other commodities, so supply chain documentation requirements remain material.

Claims regulation is the principal constraint on the nutrition segment in Europe. Commission Regulation (EU) No 379/2012 of 3 May 2012 refused to authorise certain health claims made on foods, including a joint health claim for collagen hydrolysate, and no health claim relating to collagen is authorised in the European Union register of nutrition and health claims. Collagen peptide products are therefore marketed in the European Union without a permitted health claim, which limits the communication available to brands and places the nutrition segment in a weaker position than in markets where structure and function claims are permitted. This regulatory asymmetry is a material determinant of where collagen peptide demand grows fastest.

Medical applications are the fastest-growing part of the market and the most tightly regulated. Commission Regulation (EU) No 722/2012 sets particular requirements for active implantable medical devices and medical devices manufactured utilising tissues of animal origin, requiring documented risk analysis and risk management covering sourcing, collection, handling and inactivation of transmissible agents, which applies directly to bovine and porcine collagen used in implants, wound devices and tissue repair products. These requirements raise the cost and documentation burden of supplying medical-grade collagen and restrict the number of qualified suppliers, which is why medical-grade material commands prices far above food-grade and why producers with validated sourcing and inactivation processes hold defensible positions.

The market includes large collagen and gelatin producers such as Darling Ingredients through Rousselot, GELITA, Tessenderlo Group through PB Leiner, Nitta Gelatin, Weishardt, Lapi Gelatine, Italgelatine, Junca Gelatines, Trobas Gelatine and Jellice Pioneer, specialty and regional suppliers including Ewald-Gelatine, REINERT GRUPPE Ingredients and Nippi, and medical and research-grade suppliers including Integra LifeSciences, Symatese and Advanced BioMatrix. Participants compete on raw material access and traceability, product mix and conversion capability, bloom strength, molecular weight distribution and functional consistency, regulatory documentation for pharmaceutical and medical use, religious and dietary certification, security of supply, and price per unit of functional performance.

At the same time, the market faces challenges, including raw material availability governed by livestock processing volumes rather than demand, the absence of authorised health claims for collagen in the European Union, the exposure of bovine and porcine sources to disease outbreaks and trade restrictions, religious and dietary restrictions limiting the addressable market for porcine and bovine material in several regions, price competition in commodity gelatin, and the long qualification timelines for pharmaceutical and medical applications. As a result, producers that combine secure raw material access, conversion capability into peptides and medical-grade material, complete regulatory documentation, and multi-source and certified supply are expected to capture the largest share of growth over the forecast period.